Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Gene Therapy ppRB-sup-110-phosphoprotein-the-retinoblastoma-susceptibility-gene-product

 Encapsulating biological active substances into erythrocytes
We claim: 1. A process for the encapsulation in human or animal erythrocytes of at least one ...


 Flow chamber and electro-manipulator incorporating same
Accordingly, an object of the present invention is to provide a flow chamber and an electro-...


 Electroblotting technique for transferring specimens from a polyacrylamide electrophoresis or like gel onto a membrane
What is claimed is: 1. An apparatus especially suitable for transferring a biological specimen from ...


 Probe for electrofusion, electroporation, or like procedure
The present invention provides a structure and method for treating samples in a well tray. Briefly, ...


 Device and method for the electrophoretic separation of macromolecules
The invention relates to an electrophoresis device and an electrophoresis method for the separation ...


 Superfusion apparatus
It is an object of the present invention to provide a superfusion apparatus for use in receptor ...


 Method and apparatus for administration of anticoagulant to red cell suspension output of a blood separator
OF THE PREFERRED EMBODIMENTS Referring now to the drawings, particularly to FIG. 1, there is ...


 Electroporation device
I claim: 1. An electroporation apparatus for electroporating living cells with molecules comprising:...


 Implantable electroporation method and apparatus for drug and gene delivery
Accordingly, it is the primary object of the present invention to provide an improved method of ...


 Flow electroporation chamber with electrodes having a crystalline metal nitride coating
The present invention provides improved electrodes for use in generating an electrical field in a ...


 ppRB.sup.110 -phosphoprotein the retinoblastoma susceptibility gene product

Details
Inventors: Lee, Wen-Hwa; Lee, Eva Y. - H. P.;
Assignee: The Regents of the University of California (Berkeley, CA)
Primary Examiner: Kepplinger; Esther M.
Assistant Examiner: Hoffer; Florina B.
Attorney, Agent or Firm: Kleinke; Bernard L., Waters; William Patrick, Potts; Jerry R.

This invention relates in general to a phosphoprotein product of the retinoblastoma susceptibility gene. In particular, this invention relates to a phosphoprotein ppRB.sup.110 primarily located in the cell nucleus which has a DNA binding activity. The invention also relates to the amino acid sequence of the phosphoprotein and to the specific purified anti-retinoblastoma phosphoprotein antibody. The invention further relates to a method of diagnosing retinoblastoma and other retinoblastoma gene involved cancers, treating such kind of cancers and regulating the oncogenicity of other genes.

DETAILED DESCRIPTION OF FIGURES FIG.
1 is the chromatogram illustrating the identification of RB proteins by immunoprecipitation with rabbit anti-RB IgG in various cell lines.
Human cells such as neuroblastoma LAN-1 (Lanes 1 and 2), Alexander hepatoma (Lane 3), osteosarcoma U20S (Lane 4), normal fibroblasts (Lane 5), and five retinoblastomas (Lanes 6 to 10) were labeled with .
sup.
35 S-methionine and immunoprecipitated with preimmune rabbit IgG (Lane 1) or rabbit anti-RB IgG (Lanes 2-10).
The immunoprecipitates were analyzed by 7.
5% SDS-polyacrylamide gel electrophoresis and autoradiographed.
FIG.
2 is the complete RB cDNA nucleotide sequences and predicted amino acid sequences of the RB protein.
The most 5' .
about.
240 nucleotides were obtained from a cDNA clone from retinoblastoma cell line Y79.
Nucleotide sequences from this clone and the original normal RB clones were aligned by sequence overlap.
The first and second initiation sites are boxed, and alanine and proline clusters underlined.
FIG.
3 is the chromatogram illustrating the modifications of the RB protein.
LAN-1 cells were labeled with .
sup.
35 S-methionine (lanes 1-3) or .
sup.
32 P-phosphoric acid (0.
5 mci/ml) (lanes 4 and 5) for three hours.
Cellular lysates were immunoprecipitated with preimmune rabbit IgG (lane 1 and 4) or anti-RB IgG (lanes 2, 3 and 5).
Aliquots of .
sup.
35 S-methionine-labeled RB proteins were digested with Endoglycosidase H (ICN ImmunoBiologicals) overnight (lane 3).
These immunoprecipitates were then analyzed by 7.
5% SDS-polyacrylamide gel as described in FIG.
1.
The RB gene product was found to be phosphorylated but not glycosylated.
FIG.
4 is the chromatogram illustrating a conservation of the RB gene product in different vertebrate species.
Cell lines of human neuroblastoma, LAN-5, (Lanes 1 and 2), monkey, cos, (lanes 3 and 4), quail fibroblast, QT6, (Lanes 5 and 6), mouse fibroblast, NIH/3T3, (Lanes 7 and 8), and rat fibroblast, rat-2, (Lanes 9 and 10) were labeled with .
sup.
32 P-phosphoric acid and immunoprecipitated with preimmune IgG (odd numbered lanes) or anti-RB IgG (even numbered lanes) and analyzed as described in FIG



Related patents
  Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
It has now been discovered that tumor formation in a patient can be treated or prevented by administering to the patient an antigen-presenting cell(s) that is loaded ...
  Mutants of the RB and P53 genes
OF THE INVENTION Definitions The term "functional expression of the gene" meant to include the suppression of transcription of the gene, the degradation of the gene ...
  Oncolytic virus therapy
OF THE INVENTION As used herein the term "human cells" means cells isolated from a human, or cultured cells that have been derived from cells isolated from a human and/...
  Covalently cross-linked oligonucleotides
OF THE INVENTION In accordance with the objects of this invention novel, covalently cross-linked oligonucleotide strands are disclosed. Preferably such strands are "...
  Methods of inducing cancer cell death and tumor regression
The present invention provides methods of treating cancer in a patient (e.g., a mammal such as a human) in need of such treatment, comprising administering an effective ...
  Injectable hyaluronic acid derivative with pharmaceuticals/cells
OF THE INVENTION The present invention concerns injectable, biocompatible and biodegradable compositions containing at least one hyaluronic acid benzyl ester derivative ...
  Modification of polymer surfaces and molecular immobilization by photoreaction
OF THE INVENTION To obviate disadvantages associated with the modification methods presently existing, the object of the present invention is to provide a method for ...
  Wound and skin care compositions
What is claimed: 1. A composition comprising a dermatologically acceptable carrier and an effective amount of a hydroxy acid compound, present in a concentration of ...
  Water treatment apparatus
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows: 1. Water purification apparatus for purifying dirty water,...
  Membrane cell
What we claim is: 1. A monopolar filter press electrolytic cell suitable for use in the electrolysis of an aqueous alkali metal halide solution (brine) to produce an ...

0.024

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved